Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

5-MeO-DALT

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
5-MeO-DALT
Clinical data
Trade namesFoxtrot
Other namesN,N-Diallyl-5-methoxytryptamine; 5-Methoxy-N,N-diallyltryptamine; 5-Methoxy-DALT; Foxtrot
Routes of
administration
Oral[1]
Drug classSerotonin receptor agonist;Serotonergic psychedelic;Hallucinogen
Legal status
Legal status
Pharmacokinetic data
Duration of action2–4 hours[1]
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(prop-2-en-1-yl)prop-2-en-1-amine
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H22N2O
Molar mass270.376 g·mol−1
3D model (JSmol)
  • C=CCN(CCC1=CNC2=C1C=C(OC)C=C2)CC=C
  • InChI=1S/C17H22N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h4-7,12-13,18H,1-2,8-11H2,3H3 checkY
  • Key:HGRHWEAUHXYNNP-UHFFFAOYSA-N checkY
  (verify)

5-MeO-DALT, also known asN,N-diallyl-5-methoxytryptamine or asfoxtrot, is apsychedelic drug of thetryptamine and5-methoxytryptamine families.[1][3] It is takenorally.[1]

5-MeO-DALT was firstsynthesized and described byAlexander Shulgin, who disclosed the compound in 2004.[1][4] It has been encountered as a noveldesigner andrecreational drug.[4][5]

Use and effects

[edit]

According toAlexander Shulgin in a follow-up entry to his bookTiHKAL (Tryptamines I Have Known and Loved), the dose of 5-MeO-DALT is 12 to 20 mgorally and itsduration is 2 to 4 hours.[1][6] A wider dose range of 12 to 25 mg has also been reported.[7] It is said toonset and peak remarkably quickly via the oral route, with an onset of less than 15 minutes and a time to peak of 30 minutes.[1] The effects of 5-MeO-DALT were reported by Shulgin to include positive emotional changes,lightheadedness, increased appreciation ofmusic andsex, andclosed-eye visuals.[1] There was said to be a lack ofopen-eye visuals and it was said to be relatively light inpsychedelic character.[1]

Overdose

[edit]

There is little published literature on thetoxicity of 5-MeO-DALT.[8]Case reports ofoverdose have been published, with effects includingloss of consciousness,visual hallucinations, acutedelirium, andrhabdomyolysis, among others.[8][9][10] Adeath related to behavioral intoxication has been reported.[3]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]
5-MeO-DALT activities
TargetAffinity (Ki, nM)
5-HT1A3.26–48 (Ki)
3.4 (EC50Tooltip half-maximal effective concentration)
102% (EmaxTooltip maximal efficacy)
5-HT1B551–735
5-HT1D53–107
5-HT1E322–500
5-HT1FND
5-HT2A48–218 (Ki)
11.3–139.4 (EC50)
97a–114% (
Emax)
5-HT2B45–59
5-HT2C456–1,083 (Ki)
299a (EC50)
99%a (
Emax)
5-HT3>10,000
5-HT4ND
5-HT5A3,312
5-HT687–153
5-HT787–90
α1Aα1D>10,000
α2A215–228
α2B726–956
α2C1,467–641
β1β3>10,000
D1D2>10,000
D3699
D4D5>10,000
H1505–1,373
H24,250–>10,000
H32,820 (human)
1,712 (guinea pig)
H4>10,000
M1M5>10,000
nAChTooltip Nicotinic acetylcholine receptor>10,000
I1ND
σ1333 (human)
301–398 (rodent)
σ2340 (human)
253 (rat)
TAAR1Tooltip Trace amine-associated receptor 1ND
MORTooltip μ-Opioid receptor,DORTooltip δ-Opioid receptor>10,000
KORTooltip κ-Opioid receptor899–1,132
SERTTooltip Serotonin transporter499–1,408 (Ki)
>100,000 (IC50Tooltip half-maximal inhibitory concentration) (rat)
930–22,313 (IC50) (human)
>100,000 (
EC50) (rat)
NETTooltip Norepinephrine transporter>10,000 (Ki)
>100,000 (IC50) (rat)
>100,000 (
EC50) (rat)
DATTooltip Dopamine transporter3,378 (Ki)
>100,000 (IC50) (rat)
>100,000 (
EC50) (rat)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified.Footnotes:a = Stimulation ofIP1Tooltip inositol phosphate formation.Refs:[11][12][13][14][15][16][17][18][19][20]

The interactions of 5-MeO-DALT with varioustargets have been reported.[13][14][15][19][17] It binds to a variety ofserotonin receptors, as well as a number of othertargets.[13][14][15][19][21] The drug is apotentfull agonist of theserotonin5-HT1A and5-HT2A receptors.[15][16][18][17] It is also an agonist of the serotonin5-HT2B and5-HT2C receptors.[16]

Similarly to other psychedelics, 5-MeO-DALT produces thehead-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.[7][15][14] The drug fully substitutes for theserotonergic psychedelicDOM in rodentdrug discrimination tests.[22] Conversely, 5-MeO-DALT does not substitute for theentactogenMDMA in such tests.[22] 5-MeO-DALT producesdose-dependenthyperlocomotion in rodents, followed byhypolocomotion at the highest assessed dose.[22][15] This is in contrast to many other psychedelic tryptamines, which tend to produce only hypolocomotion.[22]5-MeO-DMT and5-MeO-AMT arelocomotor depressants, whereas5-MeO-DET and5-MeO-MiPT are mixed locomotor stimulants/depressants similarly to 5-MeO-DALT.[22] It also produceshypothermia.[15]

The head-twitch response induced by 5-MeO-DALT in rodents was found to be positively related to its serotonin 5-HT2A receptor affinity and negatively related to its serotonin 5-HT1A receptor affinity.[14] In relation to this, multiple targets appear to contribute to the effects of 5-MeO-DALT.[14][5]

Pharmacokinetics

[edit]

The metabolism andcytochrome P450 inhibition of 5-MeO-DALT has been described in scientific literature.[23][24]

Chemistry

[edit]

The full name of the chemical isN-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine. It is related to the compounds5-MeO-DPT,DALT,4-HO-DALT, and4-AcO-DALT.

Synthesis

[edit]

Thechemical synthesis of 5-MeO-DALT has been described.[1]

Crystal structure

[edit]

In April 2020, Chadeayne et al. solved the crystal structure of the freebase form of 5-MeO-DALT.[25]

Analogues

[edit]

Analogues of 5-MeO-DALT includediallyltryptamine (DALT),4-HO-DALT (daltocin),4-AcO-DALT (dalcetin),5-MeO-DMT,5-MeO-DET,5-MeO-DPT,5-MeO-DiPT,5-MeO-MALT,5-MeO-MiPT, and5-MeO-iPALT (ASR-3001), among others.

History

[edit]

The first material regarding the synthesis and effects of 5-MeO-DALT was sent fromAlexander Shulgin to a research associate named Murple in May 2004, after which it was circulated online. In June 2004 5-MeO-DALT became available from internetresearch chemical vendors after being synthesized by commercial laboratories in China. In August 2004 the synthesis and effects of 5-MeO-DALT were published byErowid.[4] Shulgin has stated that 5-MeO-DALT had not previously existed in thescientific literature.[1] 5-MeO-DALT was not included in the original published version ofTiHKAL, but an entry for the compound was subsequently written and released in 2004.[4]

Society and culture

[edit]

Legal status

[edit]

China

[edit]

As of October 2015 5-MeO-DALT is a controlled substance in China.[26]

Japan

[edit]

5-MeO-DALT became a controlled substance inJapan from April 2007, by amendment to thePharmaceutical Affairs Law.[27]

Singapore

[edit]

5-MeO-DALT is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[28]

Sweden

[edit]

Sveriges riksdag added 5-MeO-DALT to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published byMedical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin.[29]

United Kingdom

[edit]

5-MeO-DALT became a Class A drug in the UK on January 7, 2015 after an update to the tryptamine blanket ban.

United States

[edit]

5-MeO-DALT is not scheduled at the federal level in theUnited States,[30] but it is likely that it could be considered an analog of5-Meo-DiPT, which is a controlled substance in USA, or an analog of anothertryptamine, in which case purchase, sale, or possession could be prosecuted under theFederal Analog Act.

Florida
[edit]

5-MeO-DALT is a Schedule Icontrolled substance in the state ofFlorida making it illegal to buy, sell, or possess in Florida.[31]

Louisiana
[edit]

5-MeO-DALT is a Schedule Icontrolled substance in the state ofLouisiana making it illegal to buy, sell, or possess in Louisiana.[32]

Research

[edit]

Cluster headache

[edit]

Anecdotal reports[33] and a small-scale trial[34] indicate the potential of 5-MeO-DALT for the treatment ofcluster headache, one of the most excruciating conditions known to medicine.[35] These observations are consistent with evidence of efficacy of other chemically-related indoleamines in the treatment of cluster headache.[36]

See also

[edit]

References

[edit]
  1. ^abcdefghijk"#56 5-MeO-DALT".Isomer Design. Retrieved28 March 2025.
  2. ^Anvisa (2023-07-24)."RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União (published 2023-07-25).Archived from the original on 2023-08-27. Retrieved2023-08-27.
  3. ^abCorkery JM, Durkin E, Elliott S, Schifano F, Ghodse AH (December 2012). "The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review".Prog Neuropsychopharmacol Biol Psychiatry.39 (2):259–262.doi:10.1016/j.pnpbp.2012.05.022.hdl:2299/12763.PMID 22683457.
  4. ^abcdMorris H, Smith A (2010-05-02)."The Last Interview With Alexander Shulgin".VICE.
  5. ^abNichols DE (2018).Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 1–43.doi:10.1007/7854_2017_475.ISBN 978-3-662-55878-2.PMID 28401524.The N,N-disubstituted compound 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT 18) has recently appeared as a new "legal high" on the illicit market (Corkery et al. 2012; Strano Rossi et al. 2014). Results from broad-based receptor screening led Cozzi and Daley (2016) to conclude that multiple serotonin receptors, as well as several non-serotonergic sites are important for the psychoactive effects of 18 and other N,N-diallyltryptamines.
  6. ^Sasha Shulgin - 5-MeO-DALT, 2C-B-FLY & 5-EtOs.Archived from the original on 2021-12-13. Retrieved3 September 2015 – viaYouTube.
  7. ^abHalberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020)."Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species"(PDF).Neuropharmacology.167 107933.doi:10.1016/j.neuropharm.2019.107933.PMC 9191653.PMID 31917152.Table 4 Human potency data for selected hallucinogens. [...]
  8. ^abDufayet L, Langrand J, Alvarez JC, Islam Larabi A (August 2022). "Loss of Consciousness and Visual Hallucinations Related to 5-MeO-DALT Intake, a Case Report Confirmed by Toxicological Analyses".J Anal Toxicol.46 (7) e186–e190.doi:10.1093/jat/bkac021.PMID 35365824.
  9. ^Kalasho A, Vibe Nielsen S (October 2016). "5-MeO-DALT; a novel designer drug on the market causing acute delirium and rhabdomyolysis".Acta Anaesthesiol Scand.60 (9):1332–1336.doi:10.1111/aas.12765.PMID 27453155.
  10. ^Jovel A, Felthous A, Bhattacharyya A (May 2014). "Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT".J Forensic Sci.59 (3):844–846.doi:10.1111/1556-4029.12367.PMID 24329118.
  11. ^"Kᵢ Database".PDSP. 28 March 2025. Retrieved28 March 2025.
  12. ^Liu T."BindingDB BDBM50435344 CHEMBL2391541".BindingDB. Retrieved28 March 2025.
  13. ^abcCozzi NV, Daley PF (February 2016)."Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines"(PDF).Bioorganic & Medicinal Chemistry Letters.26 (3):959–964.doi:10.1016/j.bmcl.2015.12.053.PMID 26739781.
  14. ^abcdefKlein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL (November 2018)."Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs"(PDF).Neuropharmacology.142:231–239.doi:10.1016/j.neuropharm.2018.02.028.PMC 6230509.PMID 29499272.
  15. ^abcdefgPuigseslloses P, Nadal-Gratacós N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, Islam MN, Holy M, Niello M, Pubill D, Camarasa J, Escubedo E, Sitte HH, López-Arnau R (August 2024)."Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties".Mol Psychiatry.29 (8):2346–2358.doi:10.1038/s41380-024-02506-8.PMC 11412900.PMID 38486047.
  16. ^abcArunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, Roth BL, Gibbons S (June 2013)."An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'".Bioorg Med Chem Lett.23 (11):3411–3415.doi:10.1016/j.bmcl.2013.03.066.PMID 23602445.
  17. ^abcKozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, Olson RJ, Janowsky A, Abbas AI (April 2023)."Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter".J Pharmacol Exp Ther.385 (1):62–75.doi:10.1124/jpet.122.001454.PMC 10029822.PMID 36669875.
  18. ^abPottie E, Cannaert A, Van Uytfanghe K, Stove CP (December 2019). "Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances".Anal Chem.91 (24):15444–15452.Bibcode:2019AnaCh..9115444P.doi:10.1021/acs.analchem.9b03104.PMID 31725281.
  19. ^abcNagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007)."The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain".Eur J Pharmacol.559 (2–3):132–137.doi:10.1016/j.ejphar.2006.11.075.PMID 17223101.
  20. ^Glatfelter GC, Clark AA, Cavalco NG, Landavazo A, Partilla JS, Naeem M (December 2024). "Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice".ACS Chem Neurosci.15 (24):4458–4477.doi:10.1021/acschemneuro.4c00513.PMID 39636099.
  21. ^Glatfelter GC, Clark AA, Cavalco NG, Landavazo A, Partilla JS, Naeem M (December 2024). "Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice".ACS Chem Neurosci.15 (24):4458–4477.doi:10.1021/acschemneuro.4c00513.PMID 39636099.
  22. ^abcdeGatch MB, Dolan SB, Forster MJ (August 2017)."Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents".Behav Pharmacol.28 (5):375–385.doi:10.1097/FBP.0000000000000309.PMC 5498282.PMID 28537942.
  23. ^Michely JA, Helfer AG, Brandt SD, Meyer MR, Maurer HH (October 2015)."Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS"(PDF).Analytical and Bioanalytical Chemistry.407 (25). Springer Science and Business Media LLC:7831–7842.doi:10.1007/s00216-015-8955-0.PMID 26297461.S2CID 26086597.
  24. ^Dinger J, Woods C, Brandt SD, Meyer MR, Maurer HH (January 2016)."Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class"(PDF).Toxicology Letters.241. Elsevier BV:82–94.doi:10.1016/j.toxlet.2015.11.013.PMID 26599973.S2CID 2384720.
  25. ^Chadeayne AR, Pham DN, Golen JA, Manke DR (April 2020)."5-MeO-DALT: the freebase ofN,N-diallyl-5-meth-oxy-tryptamine".IUCrData.5 (Pt 4) x200498. International Union of Crystallography (IUCr).Bibcode:2020IUCrD...500498C.doi:10.1107/s2414314620004988.PMC 9462216.PMID 36338299.
  26. ^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived fromthe original on 1 October 2015. Retrieved1 October 2015.
  27. ^"厚生労働省:平成18年度無承認無許可医薬品等買上調査の結果について" (in Japanese). Retrieved24 July 2015.
  28. ^"CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived fromthe original on 15 July 2015. Retrieved24 July 2015.
  29. ^Rångemark Åkerman CR (20 April 2012)."Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika"(PDF) (in Swedish). Retrieved3 September 2015.
  30. ^"§1308.11 Schedule I." Archived fromthe original on 2009-08-27. Retrieved2014-12-17.
  31. ^"Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL".Florida Statutes.
  32. ^"Louisiana State Legislature". Retrieved3 September 2015.
  33. ^Post M (2015)."Cluster Headache Patient Survey: 5-MeO-DALT".Figshare.doi:10.6084/M9.FIGSHARE.1372467.V3.
  34. ^Post M (2014)."Treatment of Cluster Headache Symptoms using Synthetic Tryptamine N,N-Diallyl-5 Methoxytryptamine".Figshare.doi:10.6084/M9.FIGSHARE.1119697.V1.S2CID 73807327.
  35. ^Brandt RB, Doesborg PG, Haan J, Ferrari MD, Fronczek R (February 2020)."Pharmacotherapy for Cluster Headache".CNS Drugs.34 (2). Springer Science and Business Media LLC:171–184.doi:10.1007/s40263-019-00696-2.PMC 7018790.PMID 31997136.
  36. ^Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA (2015-10-20). "Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey".Journal of Psychoactive Drugs.47 (5). Informa UK Limited:372–381.doi:10.1080/02791072.2015.1107664.PMID 26595349.S2CID 21948146.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
σ1
σ2
Unsorted
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=5-MeO-DALT&oldid=1323700264"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp